Biotech startups that raised Series D or later in Shanghai, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Drug Farm | Shanghai | Series D | $55.0M | 2026-07-13 |
| Full-Life Technologies | Shanghai | Series D | $109.0M | 2026-05-18 |
| CORXEL Pharmaceuticals | Shanghai | Series D | $287.0M | 2026-01-22 |
| Shende Medical Equipment Technology | Shanghai | Series D | $27.4M | 2023-10-10 |
4 rows of the CSV in 5 of its 18 columns.
- The 20 biotech startups in Shanghai, China whose last round is Series D or later have raised $2.0B in total.
- 4 of them closed their most recent round in the last 12 months, $487.9M combined.
- The largest of those rounds is CORXEL Pharmaceuticals' $287.0M Series D, dated January 2026.
- The most recent is Xgene Pharmaceutical's $36.9M Series D on 28 July 2026.
- Health care is the most common other sector, with 17 companies (85%).
- 5% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 11 to 50 employees (25% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
3 of 20| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
Table 1. Biotech startups that raised Series D or later in Shanghai, China: the 3 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 20.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 3 | Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
Table 2. Biotech startups that raised Series D or later in Shanghai, China: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | South China Venture Capital | Private equity firm | Shenzhen, China | 1 | 5% | 1 | Drug Farm |
| 2 | YD Capital | Private equity firm | Prague, Czech Republic | 1 | 5% | 1 | Drug Farm |
| 3 | BVCF | Private equity firm | Shanghai, China | 1 | 5% | 1 | Drug Farm |
| 4 | DT Capital Partners | Private equity firm | Shanghai, China | 1 | 5% | 1 | Drug Farm |
| 5 | Summer Capital | Private equity firm | Hong Kong | 1 | 5% | 1 | Full-Life Technologies |
| 6 | Sky9 Capital | Venture capital firm | 1 | 5% | 1 | Full-Life Technologies | |
| 7 | Chengwei Capital | Venture capital firm | Shanghai, China | 1 | 5% | 1 | Full-Life Technologies |
| 8 | Prosperity7 Ventures | Venture capital firm | Dhahran, Saudi Arabia | 1 | 5% | 1 | Full-Life Technologies |
| 9 | Leaps by Bayer | Corporate venture arm | Leverkusen, Germany | 1 | 5% | 1 | CORXEL Pharmaceuticals |
| 10 | RTW Investments | Hedge fund | New York, United States | 1 | 5% | 1 | CORXEL Pharmaceuticals |
| 11 | Jianxin Capital | Venture capital firm | Shanghai, China | 1 | 5% | ||
| 12 | Chongqing Venture Capital | Venture capital firm | Chongqing, China | 1 | 5% | ||
| 13 | Sinowisdom | Venture capital firm | Hangzhou, China | 1 | 5% | ||
| 14 | Zuig Investment | Private equity firm | Hangzhou, China | 1 | 5% | ||
| 15 | Jianmu Investment | Fund of funds | Minhang, China | 1 | 5% |
Table 3. Biotech startups that raised Series D or later in Shanghai, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 17 | 85% | $1.7B |
| Artificial intelligence | 2 | 10% | $138.0M |
| Software | 2 | 10% | $138.0M |
Table 4. Biotech startups that raised Series D or later in Shanghai, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 20 | 100% | $86.2M |
Table 5. Biotech startups that raised Series D or later in Shanghai, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| July 2026 | 2 | 50% | $91.9M |
| May 2026 | 1 | 25% | $109.0M |
| January 2026 | 1 | 25% | $287.0M |
Table 6. Biotech startups that raised Series D or later in Shanghai, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 20% | $487.9M |
| 2025 | 3 | 15% | $82.4M |
| 2023 | 1 | 5% | $27.4M |
| 2022 | 4 | 20% | $226.0M |
| 2021 | 2 | 10% | $105.0M |
| 2020 | 4 | 20% | $519.7M |
Table 7. Biotech startups that raised Series D or later in Shanghai, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 1 | 5% |
| 2015 to 2019 | 8 | 40% |
| 2010 to 2014 | 8 | 40% |
| Before 2010 | 3 | 15% |
Table 8. Biotech startups that raised Series D or later in Shanghai, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 11 to 50 | 5 | 25% |
| 51 to 100 | 5 | 25% |
| 101 to 250 | 3 | 15% |
| 251 to 500 | 3 | 15% |
| 501 to 1,000 | 2 | 10% |
| 1,001 to 5,000 | 1 | 5% |
| 5,001 to 10,000 | 1 | 5% |
Table 9. Biotech startups that raised Series D or later in Shanghai, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series D or later and its headquarters is in Shanghai, China. On 16 November 2026 that is 20 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 3 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 20 rows: 4 have no round amount, 0 no city and 5 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Shanghai, China whose last round is Series D or later are on the list?
- 20, in the file dated 16 November 2026. 4 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 20 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.